Rare Disease Genetic Testing Market Size & Analysis Report, 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Rare Disease Genetic Testing Market Size Analysis

Global Rare Disease Genetic Testing Market Introduction
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Immunological Disorders
  1. By Value
3. Cardiovascular Disorders
  1. By Value
4. Neurological Disease
  1. By Value
5. Endocrine and Metabolism Disorders Diseases
  1. By Value
6. Hematological Diseases
  1. By Value
7. Dermatological Disease
  1. By Value
8. Others
  1. By Value
By Specialty
1. Introduction
  1. Specialty By Value
2. Molecular Genetic Tests
  1. By Value
3. Chromosomal Genetic Tests
  1. By Value
4. Biochemical Genetic Tests
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Next-Generation Sequencing
  1. By Value
3. Sanger Sequencing
  1. By Value
4. PCR Based Testing
  1. By Value
5. Array Based Testing
  1. By Value
6. FISH
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals and Clinics
  1. By Value
3. Research Laboratories and CROs
  1. By Value
4. Diagnostic Laboratories
  1. By Value

North America Market Analysis

Introduction
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Immunological Disorders
  1. By Value
3. Cardiovascular Disorders
  1. By Value
4. Neurological Disease
  1. By Value
5. Endocrine and Metabolism Disorders Diseases
  1. By Value
6. Hematological Diseases
  1. By Value
7. Dermatological Disease
  1. By Value
8. Others
  1. By Value
By Specialty
1. Introduction
  1. Specialty By Value
2. Molecular Genetic Tests
  1. By Value
3. Chromosomal Genetic Tests
  1. By Value
4. Biochemical Genetic Tests
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Next-Generation Sequencing
  1. By Value
3. Sanger Sequencing
  1. By Value
4. PCR Based Testing
  1. By Value
5. Array Based Testing
  1. By Value
6. FISH
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals and Clinics
  1. By Value
3. Research Laboratories and CROs
  1. By Value
4. Diagnostic Laboratories
  1. By Value
U.S.
1. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Immunological Disorders
    1. By Value
  3. Cardiovascular Disorders
    1. By Value
  4. Neurological Disease
    1. By Value
  5. Endocrine and Metabolism Disorders Diseases
    1. By Value
  6. Hematological Diseases
    1. By Value
  7. Dermatological Disease
    1. By Value
  8. Others
    1. By Value
2. By Specialty
  1. Introduction
    1. Specialty By Value
  2. Molecular Genetic Tests
    1. By Value
  3. Chromosomal Genetic Tests
    1. By Value
  4. Biochemical Genetic Tests
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Next-Generation Sequencing
    1. By Value
  3. Sanger Sequencing
    1. By Value
  4. PCR Based Testing
    1. By Value
  5. Array Based Testing
    1. By Value
  6. FISH
    1. By Value
  7. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals and Clinics
    1. By Value
  3. Research Laboratories and CROs
    1. By Value
  4. Diagnostic Laboratories
    1. By Value
Canada

Europe Market Analysis

Introduction
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Immunological Disorders
  1. By Value
3. Cardiovascular Disorders
  1. By Value
4. Neurological Disease
  1. By Value
5. Endocrine and Metabolism Disorders Diseases
  1. By Value
6. Hematological Diseases
  1. By Value
7. Dermatological Disease
  1. By Value
8. Others
  1. By Value
By Specialty
1. Introduction
  1. Specialty By Value
2. Molecular Genetic Tests
  1. By Value
3. Chromosomal Genetic Tests
  1. By Value
4. Biochemical Genetic Tests
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Next-Generation Sequencing
  1. By Value
3. Sanger Sequencing
  1. By Value
4. PCR Based Testing
  1. By Value
5. Array Based Testing
  1. By Value
6. FISH
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals and Clinics
  1. By Value
3. Research Laboratories and CROs
  1. By Value
4. Diagnostic Laboratories
  1. By Value
U.K.
1. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Immunological Disorders
    1. By Value
  3. Cardiovascular Disorders
    1. By Value
  4. Neurological Disease
    1. By Value
  5. Endocrine and Metabolism Disorders Diseases
    1. By Value
  6. Hematological Diseases
    1. By Value
  7. Dermatological Disease
    1. By Value
  8. Others
    1. By Value
2. By Specialty
  1. Introduction
    1. Specialty By Value
  2. Molecular Genetic Tests
    1. By Value
  3. Chromosomal Genetic Tests
    1. By Value
  4. Biochemical Genetic Tests
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Next-Generation Sequencing
    1. By Value
  3. Sanger Sequencing
    1. By Value
  4. PCR Based Testing
    1. By Value
  5. Array Based Testing
    1. By Value
  6. FISH
    1. By Value
  7. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals and Clinics
    1. By Value
  3. Research Laboratories and CROs
    1. By Value
  4. Diagnostic Laboratories
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Immunological Disorders
  1. By Value
3. Cardiovascular Disorders
  1. By Value
4. Neurological Disease
  1. By Value
5. Endocrine and Metabolism Disorders Diseases
  1. By Value
6. Hematological Diseases
  1. By Value
7. Dermatological Disease
  1. By Value
8. Others
  1. By Value
By Specialty
1. Introduction
  1. Specialty By Value
2. Molecular Genetic Tests
  1. By Value
3. Chromosomal Genetic Tests
  1. By Value
4. Biochemical Genetic Tests
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Next-Generation Sequencing
  1. By Value
3. Sanger Sequencing
  1. By Value
4. PCR Based Testing
  1. By Value
5. Array Based Testing
  1. By Value
6. FISH
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals and Clinics
  1. By Value
3. Research Laboratories and CROs
  1. By Value
4. Diagnostic Laboratories
  1. By Value
China
1. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Immunological Disorders
    1. By Value
  3. Cardiovascular Disorders
    1. By Value
  4. Neurological Disease
    1. By Value
  5. Endocrine and Metabolism Disorders Diseases
    1. By Value
  6. Hematological Diseases
    1. By Value
  7. Dermatological Disease
    1. By Value
  8. Others
    1. By Value
2. By Specialty
  1. Introduction
    1. Specialty By Value
  2. Molecular Genetic Tests
    1. By Value
  3. Chromosomal Genetic Tests
    1. By Value
  4. Biochemical Genetic Tests
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Next-Generation Sequencing
    1. By Value
  3. Sanger Sequencing
    1. By Value
  4. PCR Based Testing
    1. By Value
  5. Array Based Testing
    1. By Value
  6. FISH
    1. By Value
  7. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals and Clinics
    1. By Value
  3. Research Laboratories and CROs
    1. By Value
  4. Diagnostic Laboratories
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Immunological Disorders
  1. By Value
3. Cardiovascular Disorders
  1. By Value
4. Neurological Disease
  1. By Value
5. Endocrine and Metabolism Disorders Diseases
  1. By Value
6. Hematological Diseases
  1. By Value
7. Dermatological Disease
  1. By Value
8. Others
  1. By Value
By Specialty
1. Introduction
  1. Specialty By Value
2. Molecular Genetic Tests
  1. By Value
3. Chromosomal Genetic Tests
  1. By Value
4. Biochemical Genetic Tests
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Next-Generation Sequencing
  1. By Value
3. Sanger Sequencing
  1. By Value
4. PCR Based Testing
  1. By Value
5. Array Based Testing
  1. By Value
6. FISH
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals and Clinics
  1. By Value
3. Research Laboratories and CROs
  1. By Value
4. Diagnostic Laboratories
  1. By Value
UAE
1. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Immunological Disorders
    1. By Value
  3. Cardiovascular Disorders
    1. By Value
  4. Neurological Disease
    1. By Value
  5. Endocrine and Metabolism Disorders Diseases
    1. By Value
  6. Hematological Diseases
    1. By Value
  7. Dermatological Disease
    1. By Value
  8. Others
    1. By Value
2. By Specialty
  1. Introduction
    1. Specialty By Value
  2. Molecular Genetic Tests
    1. By Value
  3. Chromosomal Genetic Tests
    1. By Value
  4. Biochemical Genetic Tests
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Next-Generation Sequencing
    1. By Value
  3. Sanger Sequencing
    1. By Value
  4. PCR Based Testing
    1. By Value
  5. Array Based Testing
    1. By Value
  6. FISH
    1. By Value
  7. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals and Clinics
    1. By Value
  3. Research Laboratories and CROs
    1. By Value
  4. Diagnostic Laboratories
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Disease Type
1. Introduction
  1. Disease Type By Value
2. Immunological Disorders
  1. By Value
3. Cardiovascular Disorders
  1. By Value
4. Neurological Disease
  1. By Value
5. Endocrine and Metabolism Disorders Diseases
  1. By Value
6. Hematological Diseases
  1. By Value
7. Dermatological Disease
  1. By Value
8. Others
  1. By Value
By Specialty
1. Introduction
  1. Specialty By Value
2. Molecular Genetic Tests
  1. By Value
3. Chromosomal Genetic Tests
  1. By Value
4. Biochemical Genetic Tests
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Next-Generation Sequencing
  1. By Value
3. Sanger Sequencing
  1. By Value
4. PCR Based Testing
  1. By Value
5. Array Based Testing
  1. By Value
6. FISH
  1. By Value
7. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals and Clinics
  1. By Value
3. Research Laboratories and CROs
  1. By Value
4. Diagnostic Laboratories
  1. By Value
Brazil
1. By Disease Type
  1. Introduction
    1. Disease Type By Value
  2. Immunological Disorders
    1. By Value
  3. Cardiovascular Disorders
    1. By Value
  4. Neurological Disease
    1. By Value
  5. Endocrine and Metabolism Disorders Diseases
    1. By Value
  6. Hematological Diseases
    1. By Value
  7. Dermatological Disease
    1. By Value
  8. Others
    1. By Value
2. By Specialty
  1. Introduction
    1. Specialty By Value
  2. Molecular Genetic Tests
    1. By Value
  3. Chromosomal Genetic Tests
    1. By Value
  4. Biochemical Genetic Tests
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Next-Generation Sequencing
    1. By Value
  3. Sanger Sequencing
    1. By Value
  4. PCR Based Testing
    1. By Value
  5. Array Based Testing
    1. By Value
  6. FISH
    1. By Value
  7. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals and Clinics
    1. By Value
  3. Research Laboratories and CROs
    1. By Value
  4. Diagnostic Laboratories
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Rare Disease Genetic Testing Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Quest Diagnostics Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Centogene N.V.
3billion Inc.
Invitae Corp.
Arup Laboratories
Eurofins Scientific
Ambry Genetics
Strand Life Sciences
Perkin Elmer, Inc.
Health Network Laboratories
Opko Health, Inc.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment